NCT01914159View on ClinicalTrials.gov

Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Age Related Macular Degeneration
Interventions
DRUG

Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)

Monthly intravitreal injections

Trial Locations (3)

48149

Universityof Münster, Department of Ophthalmology, Münster

53127

University of Bonn, Department of Ophthalmology, Bonn

80336

University of München (LMU), Department of Ophthalmology, München

All Listed Sponsors
lead

University Hospital, Bonn

OTHER

NCT01914159 - Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study | Biotech Hunter | Biotech Hunter